ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pan-TEAD Inhibitor ODM-212

Its studies are led by Orion Corporation, Orion Pharma.

Furthest: phase 2, since Nov 29, 20241 company-led study, 1 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Orion Corporation, Orion Pharma11 open or runningphase 2since Nov 29, 2024Nov 29, 2024Dec 31, 2027phase 2 · NCT06725758

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 29, 2024First study: phase 2 study in Solid TumoursFirst studyNCT06725758 · 315 planned · United States, Finland, France and more

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Solid TumoursNCT06725758

TargetBeta

“An orally bioavailable non-covalent small molecule inhibitor of the TEA domain (TEAD) family of transcription factors, including TEAD1, TEAD2, TEAD3 and TEAD4, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06725758Solid Tumours · United States, Finland, France and more2RecruitingDec 31, 2027315

How it is read

Names in the registry

  • “ODM-212”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.